Sivelestat Pharmacology: Network Analysis and Mouse Model Data for Myocarditis

41 potential drug targets were identified through network pharmacology analysis of the neutrophil elastase inhibitor Sivelestat for myocarditis. The dataset includes results from molecular docking and in vivo experiments on male BALB/c mice, with interventions at 50, 100, and 200 mg/kg/day. It was authored by Ruguo Ren and last updated on 2026-04-30.

Use Cases

• Validate network pharmacology predictions based on molecular docking scores like PTGS2: -9.0 kcal/mol.
• Analyze dose-response relationships in cardiac function based on Sivelestat administration at 50/100/200 mg/kg.
• Study correlations between inflammatory markers like serum IL-1β/IL-6/TNF-α and myocardial tissue expression.
• Investigate the role of PI3K-Akt signaling in anti-apoptosis based on Western blot results for p-Akt and Bcl-2.

Strengths

• Includes multi-modal validation data combining computational (41 targets) and experimental (n=6/group mouse model) results.
• Specific, quantitative outcome measures are reported, such as binding affinities and cytokine levels.
• Data is shared under a permissive CC-BY-4.0 license, facilitating reuse.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (9.7 KB), indicating limited scope, likely containing summary results rather than raw experimental data.

Provenance

Source

figshare

Collection Method

Generated from a study combining network pharmacology, molecular docking, and induced experimental autoimmune myocarditis (EAM) in mice.

Freshness

Last updated 2026-04-30 04:17:52; freshness should be verified.